NCT03658304View on ClinicalTrials.gov

Trial of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

December 5, 2018

Primary Completion Date

November 10, 2021

Study Completion Date

October 17, 2023

Conditions
Urothelial Carcinoma
Interventions
DRUG

Mitomycin c

All participants will receive a single 40 mg dose of mitomycin C intraoperatively during their scheduled nephroureterectomy. This single dose will be given through a catheter in the subject's bladder.

Trial Locations (1)

32608

University of Florida, Gainesville

All Listed Sponsors
lead

University of Florida

OTHER

NCT03658304 - Trial of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma | Biotech Hunter | Biotech Hunter